RA PHARMACEUTICALS INC's ticker is RARX and the CUSIP is 74933V108. A total of 64 filers reported holding RA PHARMACEUTICALS INC in Q3 2017. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $10,396,000 | +3.2% | 216,524 | +0.9% | 0.01% | +20.0% |
| Q4 2019 | $10,076,000 | +105.1% | 214,689 | +3.3% | 0.01% | +66.7% |
| Q3 2019 | $4,913,000 | +116.3% | 207,736 | +175.1% | 0.00% | +200.0% |
| Q2 2019 | $2,271,000 | +111.1% | 75,520 | +57.3% | 0.00% | 0.0% |
| Q1 2019 | $1,076,000 | +53.5% | 48,001 | +24.6% | 0.00% | 0.0% |
| Q4 2018 | $701,000 | +24.1% | 38,510 | +23.4% | 0.00% | – |
| Q3 2018 | $565,000 | +140.4% | 31,210 | +32.2% | 0.00% | – |
| Q2 2018 | $235,000 | +34.3% | 23,600 | -28.0% | 0.00% | – |
| Q1 2018 | $175,000 | -5.9% | 32,800 | +50.5% | 0.00% | – |
| Q4 2017 | $186,000 | -41.7% | 21,800 | 0.0% | 0.00% | – |
| Q3 2017 | $319,000 | -22.0% | 21,800 | 0.0% | 0.00% | – |
| Q2 2017 | $409,000 | +49.8% | 21,800 | +70.3% | 0.00% | – |
| Q1 2017 | $273,000 | +40.0% | 12,800 | 0.0% | 0.00% | – |
| Q4 2016 | $195,000 | – | 12,800 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| NEA Management Company, LLC | 6,138,797 | $294,724,000 | 15.40% |
| RA Capital Management | 4,858,260 | $233,245,000 | 7.37% |
| HAVENS ADVISORS LLC | 143,266 | $6,878,000 | 6.70% |
| BARDIN HILL MANAGEMENT PARTNERS LP | 609,614 | $29,267,000 | 6.40% |
| OMNI PARTNERS LLP | 1,052,744 | $50,542,000 | 4.45% |
| HBK INVESTMENTS L P | 2,004,042 | $96,214,000 | 4.03% |
| ALPINE ASSOCIATES MANAGEMENT INC. | 2,005,600 | $96,289,000 | 3.83% |
| Versor Investments LP | 1,108,845 | $53,236,000 | 3.53% |
| OXFORD ASSET MANAGEMENT LLP | 461,016 | $22,133,000 | 3.12% |
| HighVista Strategies LLC | 63,222 | $3,035,000 | 2.81% |